Weight loss medications may lead to hair loss, as indicated by recent research. An examination involving 50,000 individuals using weight loss injections like Wegovy and Mounjaro has revealed a possible association with a rare side effect known as alopecia.
Individuals taking appetite-suppressing medications have been reporting hair loss to regulatory bodies, raising concerns about the medications’ role in this issue. Although the overall risk is deemed low, an analysis of patient data from the University of Pennsylvania Health System in the US has seemingly established a connection.
According to a study published in the British Medical Journal, patients using weight loss drugs were 68% more likely to report hair loss compared to those on different diabetes treatments. Experts suggest that this hair loss could be linked to sudden decreases in calorie consumption and deficiencies in essential nutrients. The US Food and Drug Administration is currently investigating this potential side effect.
Dr. Yong Chen from the University of Pennsylvania stated that changes in weight and nutritional status are known risk factors for a type of hair loss called telogen effluvium. While this type of hair loss is usually temporary and non-scarring, it can have significant psychological impacts on individuals’ self-esteem and quality of life.
Research has identified a connection between these medications and non-scarring alopecia, where hair follicles remain intact, leaving the possibility of regrowth. However, it has not been confirmed if hair will indeed grow back.
Weekly injections like Ozempic, Wegovy, and Mounjaro work by slowing digestion and reducing appetite through mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates hunger and satiety.
Despite the efficacy of these medications, some experts, including Dr. Amir Khan from Good Morning Britain, advocate for alternative weight loss strategies. Dr. Khan emphasizes the importance of adequate sleep for weight management.
In a comparison of patients with type 2 diabetes using GLP-1 drugs versus other diabetes medications, GLP-1 users were found to have a higher risk of alopecia. Dr. Marie Spreckley, a weight management researcher from Cambridge University, highlights that while hair loss is a potential adverse effect, the benefits of GLP-1 drugs in managing diabetes and obesity outweigh this risk.
Common side effects of GLP-1 medications include vomiting and constipation. Proper support and monitoring are essential to ensure successful weight loss maintenance. While the NHS prescribes Mounjaro and Wegovy for weight loss, Ozempic is primarily recommended for diabetes management.